Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$123.83NASDAQ Previous Close - Last Trade as of 1:00PM ET 11/27/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$122.01 (1)
Ask (Size)$127.50 (4)
Day Low / HighN/A - N/A
Volume440.8 K

View Biotechnology IndustryPeer Comparison as of 11/27/2020


Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $123.83
Change: +0.90 (0.73%)
Volume: 440.8 K
1:00PM ET 11/27/2020

Seagen Inc ( NASDAQ )

Price: $169.12
Change: +3.67 (2.22%)
Volume: 488.2 K
1:00PM ET 11/27/2020

Exact Sciences Corp ( NASDAQ )

Price: $118.19
Change: +2.32 (2.00%)
Volume: 1.1 M
1:00PM ET 11/27/2020

Incyte Corp ( NASDAQ )

Price: $83.25
Change: +2.09 (2.58%)
Volume: 747.9 K
1:00PM ET 11/27/2020

Biogen Inc ( NASDAQ )

Price: $243.78
Change: +2.03 (0.84%)
Volume: 699.2 K
1:00PM ET 11/27/2020

Read more news Recent News

Analyst Actions: Bernstein Starts Alexion Pharmaceuticals at Market Perform With $148 Price Target
6:47AM ET 11/20/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) has an average rating of outperform and price targets ranging from $119 to $179, according to analysts polled by Capital IQ....

Alexion Pharmaceuticals Secures European Commission Approval for 100 mg/mL Intravenous Ultomiris
3:44AM ET 11/20/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) said Friday the European Commission has approved the new 100 mg/mL intravenous formulation of Ultomiris for the treatment of...

Marinus Pharmaceuticals Appoints Chief Commercial Officer
4:42AM ET 11/10/2020 MT Newswires

Marinus Pharmaceuticals (MRNS) appointed Christy Shafer as chief commercial officer, according to a Monday press release. Shafer most recently served as...

Alexion Pharmaceuticals Price Target Raised by Wedbush After Positive Q3 Financials
8:52AM ET 10/30/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) had its price target raised by Wedbush to $157 from $156 after the biotech's company's positive Q3 earnings report that...

Company Profile

Business DescriptionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. View company web site for more details
Address121 Seaport Boulevard
Boston, Massachusetts 02210
Number of Employees2,656
Recent SEC Filing10/29/20208-K
Chief Executive Officer & DirectorLudwig N. Hantson
President & DirectorAradhana Sarin
Chief Commercial, Global Operations Officer & EVPBrian M. Goff
Chief Information Officer & Senior Vice PresidentGeorge Llado

Company Highlights

Price Open$122.57
Previous Close$122.93
52 Week Range$72.67 - 128.57
Market Capitalization$27.1 B
Shares Outstanding218.8 M
SectorHealth Technology
Next Earnings Announcement02/04/2021

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings28.93
Earnings per Share$11.15
Beta vs. S&P 500N/A
Revenue$4.1 B
Net Profit Margin16.39%
Return on Equity8.58%

Analyst Ratings as of 11/18/2020

Consensus RecommendationConsensus Icon
Powered by Factset